CABIO(SH:688089)2020-04-29 16:00Financial Performance - Operating income decreased by 15.71% to CNY 55,722,443.40 year-on-year, primarily due to the impact of the COVID-19 pandemic[7] - Net profit attributable to shareholders increased by 13.90% to CNY 25,357,856.82, driven by higher interest and investment income[7] - Basic and diluted earnings per share decreased by 16.00% to CNY 0.21[5] - The company's net profit attributable to shareholders, excluding non-recurring gains and losses, increased by 48.60% to CNY 18,235,547.05 from CNY 12,271,422.68[16] - Total operating revenue for Q1 2020 was CNY 55,722,443.40, a decrease of 15.5% compared to CNY 66,108,482.22 in Q1 2019[26] - Net profit for Q1 2020 reached CNY 26,165,983.19, an increase of 17.5% from CNY 22,304,625.80 in Q1 2019[27] - Earnings per share for Q1 2020 was CNY 0.21, compared to CNY 0.25 in Q1 2019[27] - The total comprehensive income for Q1 2020 was CNY 26,357,781.30, compared to CNY 22,031,594.69 in Q1 2019, reflecting overall growth[27] Cash Flow - Cash flow from operating activities surged by 128.15% to CNY 59,120,168.55 compared to the same period last year[5] - Cash flow from operating activities increased by 128.15% to CNY 59,120,168.55 from CNY 25,913,088.93, mainly due to a decrease in cash paid for goods and services[16] - The net cash flow from operating activities for Q1 2020 was ¥59,120,168.55, a significant increase from ¥25,913,088.93 in Q1 2019, representing a year-over-year growth of approximately 128.5%[33] - Total cash inflow from operating activities was ¥107,686,576.36, compared to ¥102,050,839.66 in the previous year, indicating a growth of about 5.5%[33] - Cash outflow from operating activities decreased to ¥48,566,407.81 from ¥76,137,750.73, showing a reduction of approximately 36.2%[33] Assets and Liabilities - Total assets increased by 1.69% to CNY 1,319,806,915.43 compared to the end of the previous year[5] - The company's accounts receivable increased by 52.42% to CNY 13,884,336.18 compared to CNY 9,109,158.00 at the beginning of the period, mainly due to the receipt of notes that have not yet matured[15] - Total liabilities decreased to CNY 43,873,969.03 from CNY 48,256,358.50, a reduction of about 9.8%[20] - Shareholders' equity increased to CNY 1,275,932,946.40 from CNY 1,249,575,165.09, showing an increase of approximately 2.1%[20] - The total current liabilities decreased to CNY 37,606,469.03 from CNY 41,697,358.50, reflecting a reduction of about 9.5%[19] Investment and Expenses - R&D expenditure as a percentage of operating income rose by 0.94 percentage points to 6.67%[5] - The company's financial expenses decreased significantly by 343.32% to -CNY 2,955,751.47 from CNY 1,214,735.28, attributed to increased interest income and exchange gains[16] - The company's investment income surged by 3,791.20% to CNY 3,725,106.47 from CNY 95,731.62, mainly due to an increase in wealth management products[16] - Cash outflow for investments totaled ¥528,297,889.78, compared to ¥6,053,272.24 in Q1 2019, reflecting a substantial increase in capital expenditures[36] Shareholder Information - The total number of shareholders reached 9,044 at the end of the reporting period[12] - The largest shareholder, Wuhan Xinyang Bioengineering Co., Ltd., holds 44.25% of the shares[12] Other Information - The company has not disclosed any new product developments or market expansion strategies in this report[5] - Non-recurring gains and losses totaled CNY 7,122,309.78, including government subsidies and other income[10] - Other receivables decreased by 52.21% to CNY 23,926,575.20 from CNY 50,061,842.65, mainly due to the recovery of compensation from DSM in 2019[15] - Prepayments rose by 40.37% to CNY 5,104,038.49 from CNY 3,636,071.06, primarily due to an increase in prepaid energy payments[15]